Bonnecaze AK, et al. - Researchers examined the prevalence and outcomes of acute kidney injury (AKI) among patients intravenously abusing extended-release oral oxymorphone in this retrospective study. From January 2012 to December 2015, a query of electronic medical records for "drug abuse" at an academic medical center was performed and yielded 2350 subjects. They suggested that clinicians should be educated to help recognize intravenous abuse of extended-release oral oxymorphone and its associated effects. Data reported that prevalence of AKI in this population was 47.8%. Findings revealed that higher KDIGO staging seems to be correlated with slower rates of renal recovery, increased comorbidities and progression to both chronic kidney disease and end-stage renal disease.